In BCR-ABL carrying CML cells Pim inhibitors influenced cell viability and proliferation by targeting GSK3-β (glycogen synthase kinase 3 beta), mTOR, translation, and MYC/Mcl-1 [183, 184]. This evidence concerns the gene GSK3B and chronic myelogenous leukemia, BCR-ABL1 positive.